Examining Developments in Multicancer Early Detection: Highlights of New Clinical Data from Recent Conferences

Program Description

The majority of deadly cancers do not have guideline-recommended screening tests available; many cancers are detected too late, after they have progressed to late stages when chances of survival are much lower, contributing to overall cancer deaths continuing to escalate worldwide. A broad set of these cancer types have been shown to be detectable simultaneously by new, noninvasive multi-cancer early detection blood tests. These blood-based multi-cancer screening tools can potentially streamline the screening process to improve adherence and cost-effectiveness for patients. The development of new technologies for early detection of multiple types of cancer will have important clinical implications for managed care professionals involved in the identification, management, and treatment of patients with cancer. This activity will review recent and ongoing advancements and present the newest clinical data surrounding multi-cancer detection for managed care professionals to become familiar with and potentially incorporate these preventive screening into treatment paradigms for patients.

Target audience: Health-system, managed care, and oncology pharmacists
Type of activity: Application
Release date: December 3, 2021
Expiration date: December 3, 2022
Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the clinical and economic burden associated with cancer, as well as the need to engage in multi-cancer early detection to improve overall prognosis
• Investigate recent clinical updates for emerging and novel multi-cancer early detection technologies from recent conferences and publications
• Analyze the impact of new data on managed care considerations for enhancing cancer screening and care for patients with cancer

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-21-406-H01-P. The activity is available for CE credit through December 10, 2022.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, read the supplement in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Tomasz M. Beer, MD, FACP, has the following relevant financial relationships with commercial interests to disclose:
Grant/Research Support: Paid to institution; Alliance Foundation Trials, Astellas Pharma, Bayer, Boehringer Ingelheim, Corcept Therapeutics, Endocyte Inc/Advanced Accelerator Applications, Freenome, GRAIL Inc, Harpoon Therapeutics, Janssen Research & Development, Medivation Inc, SOTIO, Theraclone Sciences/OncoResponse, Zenith Epigenetics
Consultant: Arvinas, Astellas Pharma, AstraZeneca, Bayer, Constellation, GRAIL Inc, Janssen, Myovant Sciences, Pfizer, Sanofi
Stock/Shareholder: Arvinas, Salarius Pharmaceuticals

Debra Gordan, MS, has the following relevant financial relationships with commercial interests to disclose:
Stock/Shareholder: Merck, AbbVie, Organon
Spouse financial relationship: Organon

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Karleen Melody, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

Pharmacy Times® Editorial Staff—Davy James (print only)

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Medical reviewer Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: Janssen, AstraZeneca
Speakers Bureau: Pfizer

Disclosure Policy
According to the disclosure policy of The American Journal of Managed Care® and Pharmacy Times Continuing Education™, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of Pharmacy Times Continuing Education™ to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Disclosure of Unapproved/Off-Label Use
The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and they are advised to consult prescribing information for these products.

The information provided in this CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of The American Journal of Managed Care®, Pharmacy Times Continuing Education™, or any of the companies that provided commercial support for this CE activity.

Signed disclosures are on file at the office of The American Journal of Managed Care®, Cranbury, New Jersey. [CT1]

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms